Seaport Therapeutics, Inc. Common Stock
NASDAQ:SPTXBiotechnology
+$0.10 today
- Market cap
- $980.14M
- Beta
- 0.00
Volume 0.68M
Average 0.41M
SPTX Operating Expenses
Total costs of running the business that are not directly tied to producing goods or services sold.
Operating Expenses history
Currency unavailable · from the income statement
No Operating Expenses data reported for this period type.
Operating Expenses vs competitors
How SPTX compares with its peers on the latest reported figures
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $361.73M USD | +36.9% | +16.5% | 166.1% | |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $218.08M USD | -20.5% | +20.2% | — |
| LTM Mar 2026 | $209.6M USD | +141.3% | +76.5% | — | |
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | $141.71M USD | +52.6% | +129.5% | 708.6% |
CTNMContineum Therapeutics, Inc. Class A Common Stock | LTM Mar 2026 | $66.77M USD | +256.3% | +44.2% | — |
| LTM Mar 2026 | $66.42M USD | +28.9% | +25.5% | — | |
LBRXLB Pharmaceuticals Inc Common Stock | LTM Mar 2026 | $46.78M USD | — | +121.2% | — |
SPTXSeaport Therapeutics, Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding SPTX) | — | +44.8% | +44.2% | 437.3% | |
Competitors are the stored peer set for SPTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Seaport Therapeutics, Inc. Common Stock
NASDAQ:SPTX
Intrinsic Alpha fair value
Locked
Current Price
$18.31
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.